Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $66
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia maintains a 'Buy' rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $65 to $66.
August 21, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a 'Buy' rating on Blueprint Medicines and raises the price target from $65 to $66.
The raised price target by Needham analyst indicates a positive outlook for Blueprint Medicines. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100